CCM
RNAC icon

CTC Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

CTC Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$15.7K Buy
+377
New +$17.7K 0.03% 72

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CTC Capital Management's RNAC Position: Q1 2023 in Review

CTC Capital Management opened a new position in Cartesian Therapeutics (RNAC) in Q1 2023: 377 shares worth $15.7K. The stake represents 0.03% of the portfolio and ranks #72 among its holdings.

93 funds tracked by Wall St. Rank hold RNAC as of Q1 2023.

  • CTC Capital Management held 377 shares of Cartesian Therapeutics worth $15.7K as of Q1 2023.
  • Cartesian Therapeutics was a new CTC Capital Management position in Q1 2023.
  • Cartesian Therapeutics made up 0.03% of CTC Capital Management's portfolio in Q1 2023, its #72 holding.
  • 93 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2023.

Based on CTC Capital Management's 13F filing for Q1 2023, filed 5 May 2023.